The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes

Metabolism: Clinical and Experimental

Volumn 56, Issue 11, 2007, Pages 1500-1507

  Brown, Nicholas F ^a   Stefanovic Racic, Maja ^a   Sipula, Ian J ^a   Perdomo, German ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ESTERIFICATION; FATTY ACID OXIDATION; GENE EXPRESSION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCOGEN SYNTHESIS; IMMUNOBLOTTING; LIPID METABOLISM; LIPOGENESIS; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

ANIMALS; CELLS, CULTURED; HEPATOCYTES; LIPID METABOLISM; MALE; PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 35248816945     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.06.016     Document Type: Article

References (44)

1. Harris T.E., and Lawrence Jr. J.C. TOR signaling. Sci STKE 212 (2003) re15
2. Shaw R.J., and Lewis L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006) 424-430
3. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351 (2000) 95-105
4. Kahan B.D. The limitations of calcineurin and mTOR inhibitors: new directions for immunosuppressive strategies. Transplant Proc 34 (2002) 130-133
5. Hidalgo M., and Rowinsky E.K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19 (2000) 6680-6686
6. Serruys P.W., Regar E., and Carter A.J. Rapamycin eluting stent: the onset of a new era in interventional cardiology. Heart 87 (2002) 305-307
7. Dutcher J.P. Mammalian target of rapamycin (mTOR) inhibitors. Curr Oncol Rep 6 (2004) 111-115
8. Murgia M.G., Jordan S., and Kahan B.D. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 49 (1996) 209-216
9. Blum C.B. Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model. Am J Transplant 2 (2002) 551-559
10. Chavers B.M., Hardstedt M., and Gillingham K.J. Hyperlipidemia in pediatric kidney transplant recipients treated with cyclosporine. Pediatr Nephrol 18 (2003) 565-569
11. Reuben A. Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl 7 (2001) S13-S21
12. Baum C.L., Thielke K., Westin E., Kogan E., Cicalese L., and Benedetti E. Predictors of weight gain and cardiovascular risk in a cohort of racially diverse kidney transplant recipients. Nutrition 18 (2002) 139-146
13. Lopez-Talavera J.C., Garcia-Ocana A., Sipula I., Takane K.K., Cozar-Castellano I., and Stewart A.F. Hepatocyte growth factor gene therapy for pancreatic islets in diabetes: reducing the minimal islet transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation. Endocrinology 145 (2004) 467-474
14. Teutonico A., Schena P.F., and Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 16 (2005) 3128-3135
15. Brown N.F., Salter A.M., Fears R., and Brindley D.N. Glucagon, cyclic AMP and adrenaline stimulate the degradation of low-density lipoprotein by cultured rat hepatocytes. Biochem J 262 (1989) 425-429
16. Berry M.N., Edwards A.M., and Barritt G.J. Isolated hepatocytes. Preparation, properties and application (1991), Elsevier Science, Amsterdam
17. Brattstrom C., Wilczek H.E., Tyden G., Bottige Y., Sawe J., and Groth C.G. Hypertriglyceridemia in renal transplant recipients treated with sirolimus. Transplant Proc 30 (1998) 3950-3951
18. Podder H., Stepkowski S.M., Napoli K.L., Clark J., Verani R.R., Chou T.C., et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 12 (2001) 1059-1071
19. Baid-Agrawal S., Delmonico F.L., Tolkoff-Rubin N.E., Farrell M., Williams W.W., Shih V., et al. Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant patients. Transplantation 77 (2004) 1199-1202
20. Hughes S.D., Quaade C., Johnson J.H., Ferber S., and Newgard C.B. Transfection of AtT-20ins cells with GLUT-2 but not GLUT-1 confers glucose-stimulated insulin secretion. Relationship to glucose metabolism. J Biol Chem 268 (1993) 15205-15212
21. Bligh E.G., and Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37 (1959) 911-917
22. Kuhajda F.P., Pizer E.S., Li J.N., Mani N.S., Frehywot G.L., and Townsend C.A. Synthesis and antitumour activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci U S A 97 (2000) 3450-3454
23. Esser V., Brown N.F., Cowan A.T., Foster D.W., and McGarry J.D. Expression of a cDNA isolated from brown adipose tissue and heart identifies the product as the muscle form of carnitine palmitoyltransferase I (M-CPT I): M-CPT I is the predominant CPT I isoform expressed in both white (epididymal) and brown adipocytes. J Biol Chem 271 (1997) 6972-6977
24. Woeltje K.F., Kuwajima M., Foster D.W., and McGarry J.D. Characterization of the mitochondrial carnitine palmitoyltransferase enzyme system: II. Use of detergents and antibodies. J Biol Chem 262 (1987) 9822-9827
25. Perdomo G., Commerford S.R., Richard A.M., Adams S.H., Corkey B.E., O'Doherty R.M., et al. Increased beta-oxidation in muscle cells enhances insulin-stimulated glucose metabolism and protects against fatty acid-induced insulin resistance despite intramyocellular lipid accumulation. J Biol Chem 279 (2004) 27177-27186
26. Brown N.F., Hill J.K., Esser V., Kirkland J.L., Corkey B.E., Foster D.W., et al. Mouse white adipocytes and 3T3-L1 cells display an anomalous pattern of carnitine palmitoyltransferase (CPT) I isoform expression during differentiation: inter-tissue and inter-species expression of CPT I ad CPT II enzymes. Biochem J 327 (1997) 225-231
27. Ke H., and Huai Q. Structures of calcineurin and its complexes with immunophilins-immunosuppressants. Biochem Biophys Res Commun 311 (2003) 1095-1102
28. Drynan L., Quant P.A., and Zammit V.A. Flux control exerted by mitochondrial outer membrane carnitine palmitoyltransferase over β-oxidation, ketogenesis and tricarboxylic acid cycle in hepatocytes isolated from rats in different metabolic states. Biochem J 317 (1996) 791-795
29. McGarry J.D., and Brown N.F. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 244 (1997) 1-14
30. Um S.H., Frigerio F., Watanabe M., Picard F., Joaquin M., Sticker M., et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431 (2004) 200-205
31. Sipula I.J., Brown N.F., and Perdomo G. Rapamycin-mediated inhibition of mTOR in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation. Metabolism 55 (2006) 1637-1644
32. Luong N., Davies C.R., Wessells R.J., Graham S.M., King M.T., Veech R., et al. Activated FOXO-mediated insulin resistance is blocked by reduction of TOR activity. Cell Metab 4 (2006) 133-144
33. Cho H.J., Park J., Lee H.W., Lee Y.S., and Kim J.B. Regulation of adipocytes differentiation and insulin action with rapamycin. Biochem Biophys Res Commun 321 (2004) 942-948
34. Kim J.E., and Chen J. Regulation of peroxisome proliferators-activated receptor-γ activity by mammalian target of rapamycin and amino acids. Diabetes 53 (2004) 2748-2756
35. Cota D., Proulx K., Smith K.A., Kozma S.C., Thomas G., Woods S.C., et al. Hypothalamic mTOR signaling regulates food intake. Science 312 (2006) 927-930
36. Jardine A.G. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. UK Transpl Int 18 (2005) 379-384
37. Zhang N., Su D., Qu S., Tse T., Bottino R., Balamurugan A.N., et al. Sirolimus is associated with reduced islet engraftment and impaired β-cell function. Diabetes 55 (2006) 2429-2436
38. Coleman R.A., Lewin T.M., and Muoio D.M. Physiological and nutritional regulation of enzymes of triacylglycerol synthesis. Annu Rev Nutr 20 (2000) 77-103
39. Patti M.E., and Kahn B.B. Nutrient sensor links obesity with diabetes risk. Nat Med 10 (2004) 1049-1050
40. Peng T., Golub T.R., and Sabatini D.M. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol 22 (2002) 5575-5584
41. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10 (2004) 594-601
42. Hardie D.G. The AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144 (2003) 5179-5183
43. Khamzina L., Veilleux A., Bergeron S., and Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinol 146 (2005) 1473-1481
44. Drynan L., Quant P.A., and Zammit V.A. The role of changes in the sensitivity of hepatic mitochondrial overt carnitine palmitoyltransferase in determining the onset of the ketosis of starvation in the rat. Biochem J 318 (1996) 767-770